Knowledge Mapping and Research Hotspots of Generalized Pustular Psoriasis: A Bibliometric Analysis from 2003 to 2023

References

• Hu P, Wang M, Gao H, et al. The role of helper T cells in psoriasis. Front Immunol. 2021;12:788940. doi:10.3389/fimmu.2021.788940
   PubMedGoogle Scholar
• Bachelez H. Pustular psoriasis: the dawn of a New Era. Acta Derm Venereol. 2020;100(3):87–93. doi:10.2340/00015555-3388
   Google Scholar
• Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792–1799. doi:10.1111/jdv.14386
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Ruggiero A, et al. Use of biological therapies for the management of pustular psoriasis: a New Era? Clin Cosmet Invest Dermatol. 2023;16:1677–1690. doi:10.2147/ccid.S407812
   PubMed Web of Science ®Google Scholar
• Zimmermann TM, Hofmann P, Chiu GR. A narrative review of the socioeconomic burden associated with generalised pustular psoriasis. Exper Dermatol. 2023;32(8):1219–1226. doi:10.1111/exd.14841
   PubMed Web of Science ®Google Scholar
• Ellegaard O, Wallin JA. The bibliometric analysis of scholarly production: how great is the impact? Scientometrics. 2015;105(3):1809–1831. doi:10.1007/s11192-015-1645-z
   PubMed Web of Science ®Google Scholar
• Zhang J, Song L, Jia J, et al. Knowledge mapping of necroptosis from 2012 to 2021: a bibliometric analysis. Front Immunol. 2022;13:917155. doi:10.3389/fimmu.2022.917155
   PubMed Web of Science ®Google Scholar
• Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620–628. doi:10.1056/NEJMoa1013068
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907–919. doi:10.1080/1744666x.2019.1648209
   PubMed Web of Science ®Google Scholar
• Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235–1270. doi:10.1111/1346-8138.14523
   PubMed Web of Science ®Google Scholar
• Akiyama M. Pustular psoriasis as an autoinflammatory keratinization disease (AiKD): genetic predisposing factors and promising therapeutic targets. J Dermatological Sci. 2022;105(1):11–17. doi:10.1016/j.jdermsci.2021.11.009
   PubMed Web of Science ®Google Scholar
• Akiyama M, Takeichi T, Ikeda S, et al. Recent advances in clinical research on rare intractable hereditary skin diseases in Japan. Keio J Med. 2023. doi:10.2302/kjm.2023-0008-IR
   PubMed Web of Science ®Google Scholar
• Fukaura R, Akiyama M. Targeting IL-36 in inflammatory skin diseases. BioDrugs. 2023;37(3):279–293. doi:10.1007/s40259-023-00587-5
   PubMed Web of Science ®Google Scholar
• Prinz JC, Choon SE, Griffiths CEM, et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: a literature review. J Eur Acad Dermatol Venereol. 2023;37(2):256–273. doi:10.1111/jdv.18720
   PubMed Web of Science ®Google Scholar
• Löfvendahl S, Norlin JM, Schmitt-Egenolf M. Comorbidities in patients with generalized pustular psoriasis: a nationwide population-based register study. J Am Acad Dermatol. 2023;88(3):736–738. doi:10.1016/j.jaad.2022.09.049
   PubMed Web of Science ®Google Scholar
• Zheng M, Jullien D, Eyerich K. The prevalence and disease characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):5–12. doi:10.1007/s40257-021-00664-x
   PubMed Web of Science ®Google Scholar
• Zhou J, Luo Q, Cheng Y, Wen X, Liu J. An update on genetic basis of generalized pustular psoriasis (Review). Int J Mol Med. 2021;47(6). doi:10.3892/ijmm.2021.4951
   Web of Science ®Google Scholar
• Sugiura K. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants. J Dermatol Sci. 2014;74(3):187–192. doi:10.1016/j.jdermsci.2014.02.006
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Iimmunol. 2018;201(6):1605–1613. doi:10.4049/jimmunol.1800013
   PubMed Web of Science ®Google Scholar
• Furue K, Yamamura K, Tsuji G, et al. Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis. Acta Derm Venereol. 2018;98(1):5–13. doi:10.2340/00015555-2808
   PubMed Web of Science ®Google Scholar
• Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109–120. doi:10.1016/j.jaci.2016.08.056
   PubMed Web of Science ®Google Scholar
• Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013;133(11):2514–2521. doi:10.1038/jid.2013.230
   PubMed Web of Science ®Google Scholar
• Kanazawa N, Nakamura T, Mikita N, Furukawa F. Novel IL36RN mutation in a Japanese case of early onset generalized pustular psoriasis. J Dermatol. 2013;40(9):749–751. doi:10.1111/1346-8138.12227
   PubMed Web of Science ®Google Scholar
• Jordan CT, Cao L, Roberson ED, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet. 2012;90(5):796–808. doi:10.1016/j.ajhg.2012.03.013
   PubMed Web of Science ®Google Scholar
• Setta-Kaffetzi N, Simpson MA, Navarini AA, et al. AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet. 2014;94(5):790–797. doi:10.1016/j.ajhg.2014.04.005
   PubMed Web of Science ®Google Scholar
• Haskamp S, Bruns H, Hahn M, et al. Myeloperoxidase modulates inflammation in generalized pustular psoriasis and additional rare pustular skin diseases. Am J Hum Genet. 2020;107(3):527–538. doi:10.1016/j.ajhg.2020.07.001
   PubMed Web of Science ®Google Scholar
• Frey S, Sticht H, Wilsmann-Theis D, et al. Rare loss-of-function mutation in SERPINA3 in generalized pustular psoriasis. J Invest Dermatol. 2020;140(7):1451–1455.e1413. doi:10.1016/j.jid.2019.11.024
   PubMed Web of Science ®Google Scholar
• Capon F. A viewpoint on the genetic determinants of generalised pustular psoriasis. Exper Dermatol. 2023;32(8):1188–1193. doi:10.1111/exd.14746
   PubMed Web of Science ®Google Scholar
• Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012;90(5):784–795. doi:10.1016/j.ajhg.2012.03.012
   PubMed Web of Science ®Google Scholar
• Mahil SK, Twelves S, Farkas K, et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J Invest Dermatol. 2016;136(11):2251–2259. doi:10.1016/j.jid.2016.06.618
   PubMed Web of Science ®Google Scholar
• Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):13–19. doi:10.1007/s40257-021-00655-y
   PubMed Web of Science ®Google Scholar
• Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3):1021–1026. doi:10.1016/j.jaci.2018.06.038
   PubMed Web of Science ®Google Scholar
• Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2012;67(2):279–288. doi:10.1016/j.jaad.2011.01.032
   PubMed Web of Science ®Google Scholar
• Miyachi H, Konishi T, Kumazawa R, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86(6):1266–1274. doi:10.1016/j.jaad.2021.06.008
   PubMed Web of Science ®Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431–2440. doi:10.1056/NEJMoa2111563
   PubMed Web of Science ®Google Scholar
• Burden AD. Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis. Expert Rev Clin Immunol. 2023;19(5):473–481. doi:10.1080/1744666x.2023.2195165
   PubMed Web of Science ®Google Scholar
• Potestio L, Camela E, Cacciapuoti S, et al. Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023:1–8. doi:10.1080/14740338.2023.2265295
   Web of Science ®Google Scholar
• Hüffmeier U, Wätzold M, Mohr J, Schön MP, Mössner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol. 2014;170(1):202–204. doi:10.1111/bjd.12548
   PubMed Web of Science ®Google Scholar
• Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from Phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011–1017. doi:10.1111/1346-8138.13306
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, Phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355–362. doi:10.1111/1346-8138.13622
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, Ootaki K. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741–751. doi:10.1111/bjd.14702
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med. 2023;10:1243843. doi:10.3389/fmed.2023.1243843
   Web of Science ®Google Scholar
• Hagino T, Saeki H, Kanda N. Two cases of generalized pustular psoriasis successfully treated with bimekizumab. J Dermatol. 2023;50(10):e357–e358. doi:10.1111/1346-8138.16866
   PubMed Web of Science ®Google Scholar
• Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45(5):529–539. doi:10.1111/1346-8138.14294
   PubMed Web of Science ®Google Scholar
• Pavia G, Gargiulo L, Spinelli F, et al. Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab. J Eur Acad Dermatol Venereol. 2022;36(7):e502–e505. doi:10.1111/jdv.18032
   PubMed Web of Science ®Google Scholar
• Heyer S, Seiringer P, Eyerich S, et al. Acute generalized pustular psoriasis successfully treated with the IL-23p19 antibody risankizumab. J Dtsch Dermatol Ges. 2022;20(10):1362–1364. doi:10.1111/ddg.14857
   Web of Science ®Google Scholar
• Arakawa A, Ruzicka T, Prinz JC. Therapeutic efficacy of interleukin 12/interleukin 23 blockade in generalized pustular psoriasis regardless of IL36RN mutation status. JAMA Dermatol. 2016;152(7):825–828. doi:10.1001/jamadermatol.2016.0751
   PubMed Web of Science ®Google Scholar
• Matsumoto A, Komine M, Karakawa M, Kishimoto M, Ohtsuki M. Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis. J Dermatol. 2017;44(2):202–204. doi:10.1111/1346-8138.13632
   PubMed Web of Science ®Google Scholar
• Adachi A, Komine M, Hirano T, et al. Case of generalized pustular psoriasis exacerbated during pregnancy, successfully treated with infliximab. J Dermatol. 2016;43(12):1439–1440. doi:10.1111/1346-8138.13429
   PubMed Web of Science ®Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis. N Engl J Med. 2019;380(10):981–983. doi:10.1056/NEJMc1811317
   Google Scholar
• Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011;89(3):432–437. doi:10.1016/j.ajhg.2011.07.022
   Google Scholar